Eagle Pharmaceuticals (Eagle Pharmaceuticals) Cash-to-Debt : 0.21 (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eagle Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.21.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Eagle Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Eagle Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

EGRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 2.96 Max: No Debt
Current: 0.21

During the past 11 years, Eagle Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 2.96.

EGRX's Cash-to-Debt is ranked worse than
75.36% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs EGRX: 0.21

Eagle Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Eagle Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Eagle Pharmaceuticals Cash-to-Debt Chart

Eagle Pharmaceuticals Annual Data

Trend

Sep13

Sep14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

1.77

2.64

3.01

3.28

0.86

Eagle Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															0.68	0.24	0.86	0.28	0.21

Competitive Comparison of Eagle Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eagle Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Cash-to-Debt falls into.

Eagle Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Eagle Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	55.321	/	(7.784	+	56.216)
	=	0.86

Eagle Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.354	/	(9.719	+	61.896)
	=	0.21

Eagle Pharmaceuticals (NAS:EGRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Eagle Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

1E6:Germany

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677

Website

http://www.eagleus.com

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Executives

Scott Tarriff	director, officer: President and CEO	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran	officer: EVP, Chief Commercial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill	officer: Chief Financial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin	officer: Chief Medical Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp	director	C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc	director	1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein	director	HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum	director	630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers	officer: Chief Financial Officer	C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock	director	405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p.	10 percent owner	2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill	officer: Chief Scientific Officer	C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677